REFERENCES AND/OR ACKNOWLEDGEMENTS

<https://www.sciencedirect.com/science/article/pii/S2211104215002507>

No conflict of interest.

2SPD-027

MULTI-CRITERIA DECISION ANALYSIS FOR EVALUATING NEW MEDICINES IN HEALTH TECHNOLOGY ASSESSMENT FRAMEWORK ANALYSIS

¹M Torres-Novellas, ²JM Guíu Segura*, ¹CF Lastra, ¹EL Mariño, ¹P Modamio. ¹Faculty of Pharmacy and Food Sciences- University of Barcelona, Clinical Pharmacy and Pharmacotherapy Unit, Barcelona, Spain; ²Catalan Health and Social Care Consortium, Pharmacy and Medicines Area, Barcelona, Spain

10.1136/ejhp-2019-eahpconf.67

Background Escalating medicine prices have catalysed the generation of numerous 'value frameworks' with the aim of informing payers, clinicians and patients on the assessment and appraisal process of new medicines for the purpose of coverage and treatment selection decisions. Furthermore, medicine evaluation has to deal with more uncertainty, which highlights a need to determine the value of pharmacologic innovation from many issues. Multiple-criteria decision analysis (MCDA) has appeared as a methodology to address the limitations of economic evaluation in health technology assessment (HTA). However, there is limited empirical evidence from real-world applications.

Purpose The objective of this study was to review the use of the MCDA methodology as a tool for the HTA of new medicines in Europe and to determine the differences between the diverse published MCDA frameworks.

Material and methods PubMed/MEDLINE, Scopus and Web of Science databases were searched for articles published up to December 2017. Two reviewers independently screened the extracted articles for eligibility. Thirty-four articles were extracted from the full-text assessment. MCDA frameworks were identified, and criteria and use were compared between them.

Results Six main MCDA frameworks were identified from the final article list: The Value Measurement Model, The Probabilistic Model, the EUnetHTA core Model, the EVIDEM model and the Advance Value Model.

The framework models identified have common approach criteria with an impact on the treated disease, safety and clinical efficacy of medicines. Perspectives in the assessment of economics, social and ethical issues were frequent but with different approaches.

Conclusion MCDA methodology is not yet used in most European countries. Differences in criteria representation between identified frameworks demonstrates the lack of consensus in MCDA use with the HTA decision-making of new medicines. Further research is needed to optimise its use as part of policymaking.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Garattini L, Padula A. Multiple criteria decision analysis in health technology assessment for drugs: just another illusion? *Appl Health Econ Health Policy* 2017;16:1–4.

Thokala R, Duenas A. Multiple criteria decision analysis for health technology assessment. *Value Health* 2012;15:1172–81.

No conflict of interest.

2SPD-028

OPTIMISATION OF SURGICAL PROCEDURAL-KIT SETTING

¹E Laudati*, ¹A Di Mattia, ¹MS D'Antuono, ²C Polidori, ¹L Parroni. ¹Gemelli University Hospital, Pharmacy, Rome, Italy; ²University of Camerino, Camerino, Italy

10.1136/ejhp-2019-eahpconf.68

Background The Satellite Pharmacy aims to create a control management model in the use of necessary medical devices (MD) during surgical procedures and allestiment of procedural-kit containing the devices for each intervention. The planning of kit ensures the appropriateness, to monitor consumption and expenditure of the devices used, and provides useful support for the definition of requirements, budget management and risk management activities.

Purpose Our goal is the standardisation of materials, in view of the appropriateness of use of MD to improve the best clinical practice and a subsequent reduction in costs.

Material and methods The Pharmacy has collaborated in the setting of the material to be included in kits, together with the Structural Units, the Departments of Health Professions and the Directorate of Presidium. The kits, codified and associated with a usual intervention name and an ICD9CM, are used according to an established schedule. We selected the most frequent surgical procedures for each specialised branch. All the data have been collected in a single database: the surgical branch; the type of intervention; and the material used.

Results In 2016 we set up 280 types of kits for 26 781 interventions; in 2017, 281 types of kits for 26 272 interventions; and in 2018, 262 types of kits for 12 309 interventions. The new management of MD, using radiofrequency identification (RFID) technology, consists of applying a radiofrequency label on each material, allowing the tracing of each article with important information such as the lot and the deadline. This process reduces clinical risk and provides data on consumed devices from kits and those that are taken extra-kit. We analysed the consumption of extra-kit material in different surgical procedures. Specifically for thyroidectomy surgery, we found consumption of 50% extra-kit material in 2016, while in 2018 the figure was only 20%. A 30% reduction in the use of extra-kit material translates into the optimisation of kit-setting by RFID and an improvement in clinical practice.

Conclusion The optimisation of the material contained in the kits, which are constantly evolving due to obsolescence or new surgical practices, permit a standardisation of materials, increasing the appropriateness of MD and a general reduction in costs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

2SPD-029

MEDICAL DEVICES MANAGEMENT: CONSUMPTION IN SURGICAL PRACTICE WITH RADIO FREQUENCY IDENTIFICATION SYSTEM

¹E Laudati*, ¹A Di Mattia, ¹MS D'Antuono, ²C Polidori, ¹L Parroni. ¹Gemelli University Hospital, Pharmacy, Rome, Italy; ²University of Camerino, Specialisation School of Hospital Pharmacy, Camerino, Italy

10.1136/ejhp-2019-eahpconf.69

Background The Satellite Pharmacy analyses the organisation, processes, information flows and logistics related to the management of materials, mainly optimising the preparation of the